BridgeBio rises after late-stage muscular dystrophy trial success

BridgeBio Pharma (NASDAQ:BBIO) shares rose after it announced positive results from its late-stage study of BBP-418 on patients with limb-girdle muscular dystrophy type 2I/R9. The study successfully met all its main and secondary goals, showing a safety profile that aligns with ...